Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer
A. Toker, A. L. Hillis, T. D. Martin, H. E. Manchester, J. M. Hogstrom, N. Zhang, E. Lecky, N. Kozlova, N. S. Persky, D. E. Root, M. Brown, K. Cichowski, S. J. Elledge, T. Muranen, D. A. Fruman, , R. R. Madsen
This study identifies a synergistic effect between AKT inhibitors and pitavastatin in killing triple-negative breast cancer cells by targeting cholesterol trafficking.
bioRxiv · Jan 16, 2024 · PreprintCancer Biology